New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

UCLA researchers found that routine PSMA PET/CT scans could help doctors select treatment approaches for the best long-term outcomes in patients with recurring prostate cancer after surgical removal ...

A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and published in ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Study combines highly focused radiation with targeted radioactive therapy drug designed to seek out and destroy cancer cells with minimal damage to healthy tissue The Phase 2 trial, called ANDROMEDA, ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from ...